CasNo.41340-25-4,Etodolac CAS: 41340-25-4,(41340-25-4) Suppliers

1 Gram	FOB Price:USD 95.0000 -100.0000

Min.Order :1 Gram
Purity: 99%
Payment Terms : T/T,

Keywords

Etodolac CAS 41340-25-4 41340-25-4

Quick Details

Appearance:white powder
Application:Animal Pharmaceuticals
PackAge:carton boc
ProductionCapacity:1000000|Kilogram|Month
Storage:cool and dry
Transportation:ship,fly

Superiority:

Hebei Mojin Biotechnology Co., Ltd,Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.

Adenosine triphosphate can be used in the disease caused by tissue injury and activity reduction of ecto enzyme , including heart failure, carditis, miocardial infarction, cerebral arteriosclersis, coronary sclerosis, progressive muscular atrophy , cerebral hemorrhage , chronic hepatitis, cirrhosis of liver and hearing handicap, etc.

Details:

Product Detailed

Product Name:    Etodolac
Synonyms: (R)-2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid;22α-Hydroxyerythrodiol Solution, 100ppm;Etodolac Imp.(EP);Etodolac impurity;1,8-DIETHYL-1,3,4,9-TETRAHYDRO-PYRANO[3,4-B]INDOLE-1-ACETIC ACID;1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-aceticacid;4-b)indole-1-aceticacid,1,3,4,9-tetrahydro-1,8-diethyl-pyrano(;4-b]indole-1-aceticacid,1,8-diethyl-1,3,4,9-tetrahydro-pyrano[
CAS:          41340-25-4
MF: C17H21NO3
MW: 287.35
EINECS:    629-689-1
Product Categories:      APIs;Intermediates & Fine Chemicals;Pharmaceuticals;BEROTEC;Other APIs;Pharmaceutical intermediates;Heterocycles;Indole Derivatives
Mol File:    41340-25-4.mo

Description

Vonoprazan fumarate (Takecab®), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs.